In an in vivo experimental setting similar to the one used here, it has been demonstrated that anti-CD20/no-alpha mutein combination improves the survival rate of CD20+ tumor-bearing mice achieved by anti-CD20 treatment with an enhanced cytotoxic potential of NK cells and CD8+ T lymphocytes (27). The gene discussed is CD8A; the disease is neoplasm.